Cargando…
Addition of levosimendan to overcome acute cardiogenic shock—Paving the way for later heart transplantation—A first case report
Treatment of refractory cardiogenic shock has poor outcome. Levosimendan addition may help to achieve hemodynamic stabilization and improve conditions to where further treatment options such as listing for heart transplantation may become possible.
Autores principales: | Flottmann, Christian, Dumitrescu, Daniel, Sohns, Christian, Rudolph, Volker, Fox, Henrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869361/ https://www.ncbi.nlm.nih.gov/pubmed/33598259 http://dx.doi.org/10.1002/ccr3.3672 |
Ejemplares similares
-
Synergistic effects of levosimendan and convalescence plasma as bailout strategy in acute cardiogenic shock in COVID-19: A case report
por: Fox, Henrik, et al.
Publicado: (2022) -
Levosimendan in patients with acute cardiogenic shock, not responders to conventional
therapy
por: Vetrugno, L, et al.
Publicado: (2007) -
Effects of levosimendan in acute heart failure, cardiogenic and septic shock
por: Alhashemi, JA, et al.
Publicado: (2008) -
Hemodynamic and echographic effects of levosimendan in patients with cardiogenic shock refractory to catecholamines
por: Labbene, I, et al.
Publicado: (2006) -
Levosimendan therapy does not improve survival of post-resuscitation cardiogenic shock patients
por: Soos, P, et al.
Publicado: (2009)